Spirocyclic MDM2 Modulators With E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MDM2 inhibitors have limitations, necessitating the development of improved pharmaceuticals for treating cancer and other diseases such as autoimmune disorders and inflammatory disorders.
Innovation Solution
Development of a class of MDM2 inhibitors and degraders, represented by compounds of specific formulas, which include small molecule E3 ubiquitin ligase binding moieties that bind to E3 ubiquitin ligases, potentially enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MDM2 inhibitors are developed to treat cancer, then therapeutic efficacy is improved, but drug resistance and limited treatment options arise
Solution Approach 1:
The patent applies multi-functionality by designing MDM2 modulators that can operate through multiple mechanisms: they can act as inhibitors blocking MDM2-p53 interaction, as degraders inducing MDM2 degradation via E3 ubiquitin ligase recruitment, and potentially as inducers of MDM2 expression under certain conditions. This multi-modal approach addresses drug resistance by providing alternative pathways to achieve therapeutic effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical structures of MDM2 modulators, including different core scaffolds, substituent groups, and molecular weight ranges (50-500 Da). These structural parameter variations enable optimization of binding affinity, selectivity, and pharmacokinetic properties, thereby improving therapeutic efficacy while managing resistance.
2Reliability
If MDM2-p53 interaction is inhibited to promote apoptosis, then cancer cell death is enhanced, but off-target effects and toxicity may occur
Solution Approach 1:
The patent applies local quality by designing MDM2 modulators with specific molecular characteristics: small size (50-500 Da), particular functional groups, and specific binding pockets that interact with defined regions of the MDM2 protein. This localized precision in molecular design enhances selectivity for the MDM2-p53 interface while minimizing off-target interactions with other proteins or cellular components.
Solution Approach 2:
The patent uses E3 ubiquitin ligase binding moieties as intermediaries in the mechanism of action. These moieties recruit E3 ubiquitin ligases to the MDM2-modulator complex, creating an intermediary pathway that directs MDM2 for ubiquitin-mediated degradation. This intermediary mechanism provides an additional layer of specificity and reduces direct off-target effects compared to simple inhibition approaches.
3Reliability
If small molecule E3 ubiquitin ligase binding moieties are incorporated into MDM2 inhibitors, then therapeutic efficacy is enhanced, but molecular complexity increases
Solution Approach 1:
The patent merges two functional elements into a single molecular entity: the MDM2 binding pharmacophore and the E3 ubiquitin ligase binding moiety. This merging creates a bifunctional MDM2 degrader that combines target recognition with recruitment of the degradation machinery, enhancing therapeutic efficacy through a single agent rather than requiring separate compounds.
Solution Approach 2:
The patent applies segmentation by dividing the MDM2 modulator into distinct functional regions: an MDM2 binding domain, a linker region, and an E3 ligase binding domain. This segmentation allows for rational design and optimization of each component independently while maintaining overall molecular integrity. The modular structure facilitates systematic variation of individual segments to optimize efficacy while managing complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively target MDM2, offering potential therapeutic benefits for cancer, autoimmune diseases, and inflammatory disorders by modulating MDM2-p53 interaction, thereby promoting apoptosis and cell cycle arrest.
Implementation Method 1
R is H or a small molecule (e.g., molecular weight less than about 1,500 Da, 1,200 Da, 900 Da, 500 Da or less) E3 ubiquitin ligase binding moiety that binds an E3 ubiquitin ligase
Implementation Method 2
Phthalimide-based drugs, e.g., thalidomide or lenalidomide, bind to protein-degradation machinery, e.g., cereblon (CRBN; part of an ubiquitin E3 ligase complex). This may promote the recruitment of two transcription factors (IKZF1 and IKZF3) that are essential to disease progression, resulting in drug-induced ubiquitylation and degradation by the proteasome.
Implementation Method 3
resulting in drug-induced ubiquitylation and degradation by the proteasome
Data Source
AI summary
The disclosure includes compounds of Formula (I), wherein each of Z, R0, R1, R2, R3, R4, R5, R6, R, L1, L2, L3, L4, L5, L6, Q1, Q2, W, m, n, r, and s, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.